pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$RCELAVITA Medical, Inc.

$RCEL7.9000+0.64%
Valencia, CA, USupdated 15h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
7
approvals ytd
0
recalls ytd
1

Pipeline(0)

no pipeline products on record

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 6, 2026
earnings
$RCEL7.9000+0.64%
12d ago
AVITA Medical, Inc. earnings
AVITA Medical, Inc.
→
view all catalysts →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Mar 11, 26BUYO'Toole David D· CFO1,800 sh @ $4.78$9K↗
🐶 Hiring Signal
No open roles indexed yet — view AVITA Medical, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$RCEL
SEC CIK
0001762303
country
US
source
sec_tickers
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 9m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?